#31
|
|||
|
|||
Ïðè ðåâìàòîèäíîì àðòðèòå ðàçâèâàåòñÿ õðîíè÷åñêîå àóòîèììóíîå âîñïàëåíèå (èçâèíèòå, çà ïðîïèñíûå èñòèíû) è ëþáîå ââåäåíèå èç âíå êîìïîíåíòîâ ñóñòàâíîãî õðÿùà ìîæåò ñòèìóëèðîâàòü äîïîëíèòåëüíóþ âûðàáîòêó àíòèòåë. Âåäü õðÿù îáëàäàåò èììóíîëîãè÷åñêîé òîëåðàíòíîñòüþ, à ïðè ÐÀ îíà íàðóøàåòñÿ. ß áû íå ðèñêîâàëà íàçíà÷àòü õîíäðîïðîòåêòîðû ïðè ÐÀ.
2) àíàáîëè÷åñêèå ãîðìîíû ïîêàçàíû ïðè ÐÀ êàê äîïîëíèòåëüíàÿ òåðàïèÿ â ëå÷åíèè ìûøå÷íûõ àòðîôèé, à òàêæå ïðè ëå÷åíèåå ðåâìàòîèä-àññîöèèðîâàííîãî îñòåîïîðîçà. Íóæíî áóëî ñêàçàòü íå ïàòîãåíåòè÷åñêè îáîñíîâàíû, à êëèíè÷åñêè. 3) Íà ñàìîì äåëå óñòàíîâëåíèå âàðèàíòà êîñòíîãî ðåìîäåëèðîâàíèÿ èãðàåò áîëüøóþ ðîëü â ïðàâèëüíîì íàçíà÷åíèè ëå÷åíèÿ. Âîçìîæíî, ìû íå ìîæåì äîñòèãíóòü çíà÷èòåëüíîãî ïðîãðåññà â ïðèðîñòå êîñòíîé ìàññû ïðè îñòåîïîðîçå êàê ðàç ïîòîìó, ÷òî íå ó÷èòûâàåì àêòèâíîñòü êîñòíûõ êëåòîê.  ëèòåðàòóðå ýòîò âîïðîñ øèðîêî îáñóæäàåòñÿ. Òàê ïðè íèçêîì îáîðîòå ðåìîäåëèðîâàíèÿ ïîêàçàíû ñòèìóëÿòîðû, ïðè âûñîêîì - äåïðåññîðû (áèñôîñôîíàòû, íàïðèìåð). |
#32
|
||||
|
||||
Öèòàòà:
Rheumatology (Oxford). 1999 Jun;38(6):488-95. Should dehydroepiandrosterone replacement therapy be provided with glucocorticoids? Robinzon B, Cutolo M. Department of Animal Science, Faculty of Agricultural, Food and Environmental Quality Sciences, The Hebrew University of Jerusalem, Rehovot, Israel. Adrenocorticotrophic hormone (ACTH) induces the concomitant secretion of glucocorticoids (GC) and dehydroepiandrosterone (DHEA) from the adrenal cortex. Whereas GC are catabolic, DHEA is anabolic. Long-term GC administration may result in some deleterious side-effects, such as muscular weakness, atrophy and necrosis, diabetes, fattiness, osteopenia, osteoporosis and avascular necrosis and susceptibility to infections. DHEA ameliorates some deleterious effects of GC, such as diabetes, amino acid deamination, fattiness, hypertension and susceptibility to viraemia. By its anabolic effects in muscles, bones and endothelium, DHEA may diminish the severity of GC-induced myopathy, osteopenia, osteoporosis and avascular necrosis. The natural concomitant secretion of DHEA with GC probably enables the latter to protect the body from ill-effects of stress without exerting their deleterious potency. DHEA secretion diminishes during aging and severe or chronic diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Anti-inflammatory and immunosuppressive effects of GC and androgens, including DHEA, are now well established. On the other hand, administration of GC inhibits ACTH secretion, involutes the adrenal cortex and results in further DHEA deficiency, particularly harmful in chronic autoimmune diseases (i.e. RA, SLE). Therefore, the deleterious side-effects of chronic administration of GC emerges from both their direct catabolic activity and the suppression of DHEA production. Whereas, in males, most androgens come from the testes, in females, under GC supplementation, DHEA deficiency leads to nullification of the androgen-dependent anabolism, leaving them exposed to the GC-catabolic effects to a larger extent. The viewpoint presented here claims that under chronic GC supplementation, DHEA replacement therapy may reduce damage caused by GC administration. ---------------------------------------------- Z Rheumatol. 2000;59 Suppl 2:II/108-18. Replacement therapy with DHEA plus corticosteroids in patients with chronic inflammatory diseases--substitutes of adrenal and sex hormones. Straub RH, Scholmerich J, Zietz B. Laboratory of Neuroendocrinoimmunology, Department of Internal Medicine I, University Hospital, Franz-Josef-Strauss-Allee 11, D-93042 Regensburg, Germany. A dysfunction of the hypothalamic-pituitary-adrenal (HPA) axis was found in animal models of chronic inflammatory diseases, and the defect was located in more central portions of the HPA axis. This defect of neuroendocrine regulatory mechanisms contributes to the onset of the model disease. Since these first observations in animal models were made, evidence has accumulated that the possible defect in the HPA axis in humans is more distal to the hypothalamus or pituitary gland: In chronic inflammatory diseases, such as rheumatoid arthritis, an alteration of the HPA stress response results in inappropriately low cortisol secretion in relation to adrenocorticotropic hormone (ACTH) secretion. Furthermore, it has recently been shown that the serum levels of another adrenal hormone, dehydroepiandrosterone (DHEA), were significantly lower after ACTH stimulation in patients with rheumatoid arthritis without prior corticosteroids than in healthy controls. These studies clearly indicate that chronic inflammation alters, particularly, the adrenal response. However, at this point, the reason for the specific alteration of adrenal function in relation to pituitary function remains to be determined. Since one of the down-regulated adrenal hormones, DHEA, is an inhibitor of cytokines due to an inhibition of nuclear factor-kappa B (NF-kappa B) activation, low levels of this hormone may be deleterious in chronic inflammatory diseases. We have recently demonstrated that DHEA is a potent inhibitor of IL-6, which confirmed an earlier study in mice. Since IL-6 is an important factor for B lymphocyte differentiation, the missing down-regulation of this cytokine, and others such as TNF, may be a significant risk factor in rheumatic diseases. Since in these patients, administration of prednisolone or the chronic inflammatory process itself alters adrenal function, endogenous adrenal hormones in relation to proinflammatory cytokines change. Furthermore, these mechanisms may also lead to shifts in steroidogenesis which have been demonstrated in chronic inflammatory diseases. It was repeatedly demonstrated that the serum level of the sulphated form of DHEA (DHEAS) was significantly lower in patients with chronic inflammatory diseases. Since DHEAS is the pool for peripheral sex steroids, such as testosterone and 17 beta-estradiol, lack of this hormone leads to a significant sex hormone deficiency in the periphery. This overview will demonstrate mechanisms why DHEAS is reduced in chronic inflammatory diseases. The importance of DHEAS deficiency will be demonstrated with respect to osteoporosis. As a consequence, we suggest a combined therapy with corticosteroids plus DHEA in chronic inflammatory diseases. ---------------------------------------- Trends Endocrinol Metab. 2002 Sep;13(7):288-94. DHEA treatment: myth or reality? Allolio B, Arlt W. Dept Medicine, Endocrine and Diabetes Unit, University of Wurzburg, Josef-Schneider-Str. 2, 97080 Wurzburg, Germany. ...DHEA has considerable effects on mood, well-being and sexuality in patients with adrenal insufficiency, and also in those with mood disorders. However, subjects with a physiological, age-related decline in DHEA secretion show little benefit from DHEA administration. Future research should focus on DHEA treatment for adrenal insufficiency, and DHEA administration in both patients receiving chronic glucocorticoid treatment and women with androgen deficiency.
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#33
|
|||
|
|||
Öèòàòà:
Öèòàòà:
Öèòàòà:
Îñòàåòñÿ íå òàê ìíîãî: ôòîðèäû âðîäå áû ÷àñòîòó ïåðåëîìîâ íå î÷åíü óìåíüøàþò.. ïàðàò-ãîðìîí, èïðèôëàâîí, îññåèí-ãèäðîêñèàïàòèòíûé êîìïëåêñ ìàëîèçó÷åíû |
#34
|
|||
|
|||
Äîáðûé âå÷åð!
Ïîëó÷èëè ðåçóëüòàòû áèîõèìè÷åñêîãî àíàëèçà: Îáùèé áåëîê 71 g/l Àëüáóìèí 43 g/l Ìî÷åâèíà 4,8 mmol/l Êðåàòèíèí 53 mkmol/l Ìî÷åâ. ê-òà 211 mkmol/l Õîëåñòåðèí 6,40 mmol/l (íîðìà äî 5,2) Òðèãëèöåðèäû 2,55 mmol/l (äî 1,90) Áèëèðóáèí îáùèé 4,9 mkmol/l Êàëüöèé 2,08 mmol/l (îò 2) Æåëåçî 7,10 mkmol/l (îò 8,8) ALT 16 me/l ACT 25 me/l Ãëþêîçà 3,60 mmol/l (îò 3,80) Àëüôà-àìèëàçà 33 me/l Ëàêòàòðåãèäðîãåíàçà 518 me/l (äî 450) Êðåàòèíêèíàçà 44 me/l Êàêèå åùå àíàëèçû íóæíî ñäàòü? Ïðîøó ïðîùåíèÿ, åñëè åñòü îøèáêè... |
#35
|
|||
|
|||
Íàøëà ðåçóëüòàò îáñëåäîâàíèÿ çà ñåíòÿáðü 2004 ã ïî ïëîòíîñòè:
Øåéêà ïðàâîãî áåäðà T - 4, Ïîÿñíè÷íîãî îòäåëà ïîçâîíî÷íèêà Ò - 3,7 Ïåðåëîì áûë ëåâîé øåéêè áåäðà òðè ãîäà íàçàä. |
#36
|
||||
|
||||
Óâàæàåìàÿ Àðèêà!
Êîíå÷íî, íóæíî ñíèæàòü õîëåñòåðèí è òðèãëèöåðèäû - ëó÷øèé âàðèàíò àòîðâàñòàòèí+ïîëèíåíàñûùåííûå æèðíûå êèñëîòû (ðûáèé æèð, ýêñòðàêò), òê ïîòðåáóåòñÿ êàê ìèíèìóì ñíèæåíèå íà 40-50%, ÷òî êîíå÷íî ñëîæíî íà îäíèõ ñòàòèíàõ. Àòîðâàñòàòèí ñåáÿ íåïëîõî ïîêàçàë ïðè ëå÷åíèè ÐÀ, äà è îñòåîïîðîòè÷. ïåðåëîìû ñòàòèíû ïîõîæå òàêæå ïðåäîòâðàùàþò. Ïî æåëåçó - íóæíî ïåðåñäàòü îáù. æåëåçîñâÿç. ñïîñ. ñûâîðîòêè è òîãäà ðåøàòü âîïðîñ î ïóòÿõ êîððåêöèè (àíåìèÿ â îáù. àíàëèçå êðîâè åñòü?).
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#37
|
|||
|
|||
Öèòàòà:
Ñïàñèáî áîëüøîå çà öåííûå ðåêîìåíäàöèè. Äåëî â òîì, ÷òî ìàìà íå ïðèíèìàåò Àòîðâàñòàòèí, ò.ê. íèêòî íå íàçíà÷àë (à ïî êàêîìó ïîâîäó åãî ïüþò?). Ïðè âûïèñêå èç á-öû ïî ïîâîäó ïåðåëîìà øåéêè áåäðà ñòàâèëè àíåìèþ. Êðîâü èç ïàëüöà âîçüìóò çàâòðà. ×åñòíî ãîâîðÿ, ìàìà äîñòàòî÷íî ðàñïîëíåëà (ì.á. èç-çà òîãî, ÷òî áðîñèëà êóðèòü 2 ãîäà íàçàä, ì.á. èç-çà Ìåòèïðåäà), îâîùè íå åñò, ãîâîðèò, ÷òî äèàðåÿ ó íåå îò íèõ, ïîêóïàþ âñÿêèå ñëàäîñòè, êðàñíóþ ðûáå ïðåäïî÷èòàåò ñåëåäêó, õîòÿ, ïîêóïàþ è òî è äðóãîå ïîñòîÿííî Êàêîé äîëæåí áûòü ðàöèîí ïðè òàêèõ ïîêàçàòåëÿõ è çàáîëåâàíèÿõ? Ñïàñèáî. |
|
#38
|
|||
|
|||
Öèòàòà:
À êàê âñå ýòî ñîñòûêóåòñÿ ñ òåìè ëåêàðñòâàìè, êîòîðûå îíà ïðèíèìàåò? |
#39
|
||||
|
||||
Àòîðâàñòàòèí (ñòàòèíû) ïðèíèìàþò ïðè ïîâûø. õîëåñòåðèíå äëÿ ïðîôèëàêòèêè ñîñóäèñòûõ ýïèçîäîâ (èíôàðêòîâ, èíñóëüòîâ) è ïðåäîòâðàùåíèè ñìåðòè îò ÑÑÇ.
Åñëè âìåñòî êðàñíîé ðûáû ïðåäïî÷òåíèå îòäàåòñÿ ñåëåäêå, òî ñòîèò ïîäóìàòü î ïðèîáðåòåíèè êàïñóëüíîé äîáàâêè ñ ýòèìè âåùåñòâàìè (íóæíî óçíàòü, ÷òî åñòü ïðèëè÷íîãî â Âàøèõ àïòåêàõ) eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Ïîäðîáíåå [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Åñëè íå èäóò îâîùè, òî ÷òî ñ ôðóêòàìè? Íå çíàþ, åñòü ëè â Ìîñêâå, íî ìîæíî è ðàñòâîðèìûå ïèù. âîëîêíà (dietary fiber supplement).
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#40
|
||||
|
||||
Íå çíàþ, êàê áóäåò "ñòûêîâàòüñÿ", íî íå èñêëþ÷àåòñÿ è àääèòèâíûé ýôôåêò: è àòîðâàñòàòèí è ðûáèé æèð íåïëîõî çàðåêîìåíäîâàëè ñåáÿ ïðè ëå÷åíèè è ÐÀ.
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#41
|
|||
|
|||
Çíà÷èò, ñòàòèíû íóæíî ïðèíèìàòü â ëþáîì ñëó÷àå è êîíôëèêòà ñ äð.
ïðåïàðàòàìè íå áóäåò, ïðàâèëüíî? Ôðóêòû åñò, íî ïî÷åìó-òî íåìíîãî: áàíàíû, ÿáëîêè, ìàíäàðèíû è ïî ñåçîíó. |
#42
|
||||
|
||||
Ñî ñòàòèíàìè íåëüçÿ ãðåèïôðóòîâûé ñîê, àçîëîâûå àíòèìèêîòèêè, ìàêðîëèäíûå àíòèáèîòèêè, áëîêàòîðû êàëüö. êàíàëîâ, ñåëåêò. èíãèáèò. îáðàòíîãî çàõâàòà ñåðîòîíèíà - îíè ïîâûøàþò êîíöåíòðàöèþ ñòàòèíà â êðîâè è ìîãóò âûçâàòü ïîá. äåéñòâèÿ.
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#43
|
||||
|
||||
Êàê êîëëåãè ìîãóò ïðîêîììåíòèðîâàòü íåäàâíèå íîâîñòè?
(Ê ñîæàëåíèþ, íå âèäåë ïîëíîé âåðñèè) Áèîäîáàâêè ñ êàëüöèåì è âèòàìèíîì Ä áåñïîëåçíû äëÿ ïîæèëûõ Óïîòðåáëåíèå ïîæèëûìè ëþäüìè áèîëîãè÷åñêè àêòèâíûõ äîáàâîê ê ïèùå, ñîäåðæàùèõ êàëüöèé è âèòàìèí Ä, íå ïðåäîòâðàùàåò ïîÿâëåíèÿ îñòåîïîðåòè÷åñêèõ ïåðåëîìîâ, ñîîáùàåò Agence France Presse. Äåôèöèò âèòàìèíà Ä îáû÷íî ðàññìàòðèâàëñÿ â êà÷åñòâå îñíîâíîé ïðè÷èíû âîçíèêíîâåíèÿ ïåðåëîìà ïðè îñòåîïîðîçå, ïîýòîìó ñ ïðîôèëàêòè÷åñêîé öåëüþ ïîæèëûì ÷àñòî íàçíà÷àþòñÿ ïðåïàðàòû êàëüöèÿ è âèòàìèíà Ä. Îäíàêî ãðóïïà ó÷åíûõ èç Àáåðäèíñêîãî óíèâåðñèòåòà (Aberdeen University), Øîòëàíäèÿ, ïîä ðóêîâîäñòâîì ïðîôåññîðà Àäðèàíà Ãðàíòà (Adrian Grant), îïóáëèêîâàâøàÿ ðåçóëüòàòû èññëåäîâàíèé â àïðåëüñêîì íîìåðå æóðíàëà The Lancet, óñòàíîâèëà, ÷òî äàííàÿ ãèïîòåçà íå íàõîäèò ïîäòâåðæäåíèÿ. Áûëè èçó÷åíû 5300 ÷åëîâåê (85 ïðîöåíòîâ èç íèõ - æåíùèíû) â âîçðàñòå ñòàðøå 70 ëåò, ñòðàäàþùèõ îñòåîïîðîçîì è â òå÷åíèå 10 ïðîøåäøèõ ëåò ïåðåíîñèâøèõ ðàçëè÷íûå ïåðåëîìû. Âñå èññëåäóåìûå áûëè ðàçäåëåíû íà 4 ãðóïïû: ïåðâîé äàâàëè òîëüêî ïðåïàðàòû âèòàìèíà Ä, âòîðîé - òîëüêî êàëüöèé, òðåòüåé - êàëüöèÿ è ïðåïàðàòû âèòàìèíà Ä, ÷åòâåðòàÿ ãðóïïà ïîëó÷àëà ïëàöåáî. Çà 5 ëåò èçó÷åíèÿ ïåðåëîìû íàáëþäàëèñü ó 13 ïðîöåíòîâ ïàöèåíòîâ, ïðè÷åì íåçàâèñèìî îò òîãî, â êàêîé èìåííî ãðóïïå îíè íàõîäèëèñü. Ñëåäóåò îòìåòèòü, ÷òî çà ïåðèîä íàáëþäåíèÿ áîëåå òðåòè èñïûòóåìûõ (36 ïðîöåíòîâ) ïðåêðàòèëè ïðèåì ïðåïàðàòîâ, òàê êàê íà÷àëè èñïûòûâàòü ïðîáëåìû ñ ïèùåâàðåíèåì, à åùå 9 ïðîöåíòîâ ïàöèåíòîâ çà ýòî âðåìÿ óìåðëè. Doubt over calcium and vitamin D supplements for protection against bone fractures. Calcium and vitamin D supplements are often recommended for older people to help protect against bone fractures. An Early Online study in The Lancet does not show any benefit of calcium and vitamin D, alone or in combination, on fracture recurrence among older people. An accompanying Comment states that the study findings should be interpreted with caution for several reasons, including the unknown baseline vitamin D status of many of the study participants. The Lancet Early Online Publication, 28 April 2005 Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial The RECORD Trial Group Summary Background Elderly people who have a fracture are at high risk of another. Vitamin D and calcium supplements are often recommended for fracture prevention. We aimed to assess whether vitamin D3 and calcium, either alone or in combination, were effective in prevention of secondary fractures. Methods In a factorial-design trial, 5292 people aged 70 years or older (4481 [85%] of whom were women) who were mobile before developing a low-trauma fracture were randomly assigned 800 IU daily oral vitamin D3, 1000 mg calcium, oral vitamin D3 (800 IU per day) combined with calcium (1000 mg per day), or placebo. Participants who were recruited in 21 UK hospitals were followed up for between 24 months and 62 months. Analysis was by intention-to-treat and the primary outcome was new low-energy fractures. Findings 698 (13%) of 5292 participants had a new low-trauma fracture, 183 (26%) of which were of the hip. The incidence of new, low-trauma fractures did not differ significantly between participants allocated calcium and those who were not (331 [12·6%] of 2617 vs 367 [13·7%] of 2675; hazard ratio (HR) 0·94 [95% CI 0·81–1·09]); between participants allocated vitamin D3 and those who were not (353 [13·3%] of 2649 vs 345 [13·1%] of 2643; 1·02 [0·88–1·19]); or between those allocated combination treatment and those assigned placebo (165 [12·6%] of 1306 vs 179 [13·4%] of 1332; HR for interaction term 1·01 [0·75–1·36]). The groups did not differ in the incidence of all-new fractures, fractures confirmed by radiography, hip fractures, death, number of falls, or quality of life. By 24 months, 2886 (54·5%) of 5292 were still taking tablets, 451 (8·5%) had died, 58 (1·1%) had withdrawn, and 1897 (35·8%) had stopped taking tablets but were still providing data for at least the main outcomes. Compliance with tablets containing calcium was significantly lower (difference: 9·4% [95% CI 6·6–12·2]), partly because of gastrointestinal symptoms. However, potentially serious adverse events were rare and did not differ between groups. Interpretation The findings do not support routine oral supplementation with calcium and vitamin D3, either alone or in combination, for the prevention of further fractures in previously mobile elderly people.
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#44
|
||||
|
||||
×òî-òî íå òî- îñòåîïîðîç- ÇÀÁÎËÅÂÀÍÈÅ, è ïðèåì êàëüöèÿ è âèò. Ä íèêîãäà íå ðàññìàòðèâàëñÿ êàê îñíîâíîé ìåòîä ëå÷åíèÿ ÇÀÁÎËÅÂÀÍÈß.
Ìû âñåãäà ïèñàëè, ÷òî ïðîôèëàêòêà- êàëüöèé è Äç, ëå÷íåèå- îíûå + ìèàêàëüöèê\ ôîñàìàêñ\ è ïð.
__________________
Ã.À. Ìåëüíè÷åíêî |
#45
|
||||
|
||||
Óâàæàåìàÿ Ãàëèíà Àôàíàñüåâíà!
Ò.å., åñëè ñóùåñòâóåò ðèñê îñòåîïîðîçà, òî äëÿ åãî ïðîôèëàêòèêè (è ñîîòâåòñòâåííî ÏÅÐÂÈ×ÍÛÕ ïåðåëîìîâ) êàëüöèé+âèò.Ä; åñëè îñòåîïîðîç ñóùåñòâóåò êëèíè÷åñêè (óæå áûëè ïåðåëîì(û) â àíàìíåçå), òî ýòî ñî÷åòàíèå äëÿ ïðîôèëàêòèêè ÂÒÎÐÈ×ÍÛÕ ïåðåëîìîâ íå ðàáîòàåò, à íóæíû áèôîñôîíàòû è ïðî÷. âèäû ëå÷åíèÿ. Ìîæíî ëè ïîëàãàòü, ÷òî íà îñíîâàíèè ýòîé ðàáîòû áóäåò îòñóòñòâîâàòü àääèòèâíûé ýôôåêò îò Ñà+âèò.Ä ïðè ñî÷åòàíèè ñ òåìè æå áèôîñôîíàòàìè, äëÿ êîòîðûõ äîêàçàíî çàùèòíîå äåéñòâèå îò âòîðè÷íûõ ïåðåëîìîâ, à çíà÷èò ëó÷øå ñîñðåäîòî÷èòüñÿ ïðåèìóùåñòâåííî íà äîêàçàííûõ ïð-òàõ äëÿ ïðåäóïðåæäåíèÿ ÂÒÎÐÈ×ÍÛÕ ïåðåëîìîâ?
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |